ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival

June 24, 2011

NCI Funds; Ad Hoc Group Approves NCCTG Renewal

September 18, 1981

Big Community Programs Under Way In Detroit, N.M.; Others Near OK

January 14, 1977

Annual Report Key Element In Prevention Drive, Maquire Insists

February 2, 1979

Genetic Test Identifies Patients With High Risk of Mortality

November 30, 2012

FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA

July 3, 1981